Table 4.
Molecular differences between primary tumors and PDX.
| CODE | TYPE | GENETIC ALTERATIONS | TUMOR CELLULARITY (%) | VAFPRIM.TUMOR | VAFPDX |
|---|---|---|---|---|---|
| 105 | LUSC |
TP53:c.469G>T:p.V157F KMT2C:c.918T>G:p.Y306* |
90 |
0.057 0.059 |
1 0.062 |
| 110 | LUSC |
TP53:c.413C>T:p.A138V ALK:c.2712T>A:p.H904Q |
85 |
0.432 0.36 |
0.952 0.191 |
| 112 | PLEIO/LUAD | CTNNB1:c.98C>T:p.S33F TP53:c.811G>T:p.E271* STK11:c.487G>T:p.G163C KDR:c.2761delinsAT:p.F921Ifs*13 KDR:c.2757C>G:p.C919W |
80 | 0.49 0.436 0.356 0.316 0.317 |
0.868 0.93 0.895 0.83 0.831 |
| 302 | LUSC | KIT:2508G>T:p.M836I EGFR:c.1150A>T:p.T384S, MEN1:c.184A>G:p.T62A, MET:c.1241A>G:p.D414G |
70 | 0.28 0.392 0.325 0.64 |
0.973 0.993 0.644 0.995 |
| 512 | LUSC |
TP53:c.845G>C:p.R282P CDKN2A:c.316_317T:p.V106Cfs*39 PDGFRA:c.1102G>C:p.E368Q |
75 |
0.336 0.375 0.4 |
0.999 0.998 0.995 |
| 517 | LUSC | RB1:c.852delinsTA:p.I285Nfs*2 | 75 | 0.249 | 0.998 |
| 518 | LUSC | TP53:c.659A>G:p.Y220C | 80 | 0.304 | 0.996 |
| 519 | LCNEC | RB1:c.1953_1954T:p.V654Cfs*3 | 80 | 0.732 | 0.998 |
| 531 | LUSC |
TP53:c.747G>T:p.R249S
CDKN2A:c.262G>T:p.E88* PIK3CA:c.1633G>A:p.E545K |
80 |
0.574
0.416 0.251 |
0.998
0.991 0.337 |
| 546 | LUAD |
KRAS:c.35G>A:p.G12D ATM:c.8851G>A:p.V2951I |
85 |
0.342 0.371 |
0.296
0.997 |
| 551 | LUSC | MTOR c.1333A>G:p.R445G CDKN2A:c.61G>C:p.A21P |
65 | 0.686 0.295 |
0.994 0.966 |
| 568 | LUAD |
TP53:c.880G>T:p.E294*
KRAS:c.34G>T:p.G12C |
65 |
0.09
0.16 |
0.63
0.62 |
| 569 | LUSC |
NF1:c.4662-1G>T TP53:c.994-2A>T; SMAD4:c.1326G>T:p.Q442H |
80 |
0.301
0.274 0.145 |
0.984
0.991 0.953 |
| 571 | LUSC |
CHEK2: c.1114C>T:p.Q372* TP53:c.994-2A>T BRCA2:c.3668A>G:p.H1223R NOTCH1:c.2058_2059T:p.C687Afs*84 |
75 | 0.294 0.287 0.59 0.279 |
0.362 0.952 0.959 0.951 |
Pathogenic events are shown in bold.